Table 1 Clinical patient characteristics
From: The CD31 molecule: a possible neuroprotective agent in acute ischemic stroke?
Characteristic | n = 86 |
|---|---|
Age (years): median, range | 72, 21–92 |
Sex | |
Female | 40 (47%) |
Occlusion site | |
MCA | 50 (58%) |
ICA including carotid-T | 22 (26%) |
Combined ICA and MCA/ACA | 13 (15%) |
ACA | 1 (1%) |
Baseline NIHSS (range, median), n = 81 (94.2%) | 15, 2–27 |
IV rtPA | 57 (66%) |
Time symptom onset to reperfusion (min): median, range, n = 70 (81.4%) | 280 (0–495) |
mRS (90 days), n = 41 (47.7%) | |
0–2 | 17 (39.1%) |
> 2 | 24 (60.9%) |
Stroke etiology (TOAST), n = 85 | |
1 = arterioembolic | 16 (18.8%) |
2 = cardioembolic | 40 (47.1%) |
4 = other determined cause | 9 (10.6%) |
5 = cryptogenic | 20 (23.5%) |